0 items USD 0.00Therapeutic Market of Narcolepsy in Seven Major Markets Shall Reach up to USD 2.4 Billion by 2027
Narcolepsy is a chronic neurological / brain disorder which involves poor control of sleep and wakefulness.
The disease is classically a tetrad of symptoms including excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, and hypnagogic hallucinations. People suffering from narcolepsy experience periods of excessive daytime sleepiness and sudden uncontrollable episodes of falling asleep during any time of the day.
It occurs in both men and women and affects about 1 in 2000 people. Also, misdiagnosis is common and a recent study showed that 60% of patients were misdiagnosed. It has been estimated that only 25% people suffering from narcolepsy get diagnosed and receive treatment. As per the KOL (Key Opinion Leaders) views, Narcolepsy accounts for approximately 94% of all cases in adult patients whereas 6% of all cases in pediatric population.
According to new report estimation, the total prevalent population of Narcolepsy in 7 major markets was calculated to be 0.5 Million in 2016.
Pharmacological therapies are the most frequent approach for treating the signs and symptoms associated with the Narcolepsy. Among those therapies, Modafinil/Armodafinil, Xyrem (Sodium Oxybate) are used as the first line of therapies for the treatment of Excessive Daytime Sleepiness (EDS) associated with Narcolepsy whereas Xyrem (Sodium Oxybate) and Venlafaxine are recommended as the first line of therapies for the treatment of Cataplexy associated with Narcolepsy.
Stimulants, such as amphetamines/dextroamphetamines and methylphenidate, are the conventional medications prescribed for the management of Excessive Daytime Sleepiness (EDS) associated with Narcolepsy.
The United States accounts for the highest market size of Narcolepsy as compared to the EU5 countries (United Kingdom, France, Germany, Spain and Italy) and Japan. Report estimates suggest that the therapeutic market of Narcolepsy in seven major markets shall reach up to USD 2.4 Billion by 2027.
Launch of the upcoming therapies such as BTD-001 (Balance Therapeutics) in March 2022 in United States, JZP-258 (Jazz Pharmaceuticals) in July 2020, JZP-110 (Jazz Pharmaceuticals) shall increase the market size. Also, the launch of Xyrem (Jazz Pharmaceuticals) for pediatric patients and Wakix (Bioprojet Pharma) for the Narcolepsy in adult patients with and without cataplexy shall influence the market in coming years.
Overall, the increasing diagnosed prevalence of the disease along with the promising emerging pipeline therapies will fuel the market during the forecasted period of 2018-2027.
List of Companies | |
Pipeline Products | Marketed Products |
|
|
|
|
|
|
|
|
|
|
|
|
Gain More Insight on Narcolepsy- Market Insight, Epidemiology and Market Forecast - 2027
Email a colleague
Printer version
Send by email
About The Author
Staff Member
